StockData

Gossamer Bio vs Keros Therapeutics

GOSS and KROS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GOSS and KROS compare

Gossamer Bio is the larger company, worth 24 times as much as Keros Therapeutics ($5.4B against $224M).

Gossamer Bio grew revenue faster over the last twelve months (32.4% versus −93.7% for Keros Therapeutics).

Gossamer Bio keeps more of each dollar of sales as profit, with a net margin of −235% compared with −572% at Keros Therapeutics.

Keros Therapeutics scores higher on the StockData Score (7 against 1 for Gossamer Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGOSSKROS
Size and price
Market cap$5.4B$224M
Share price$11.04$11.31
Change, 1 year−94.9%−34.5%
Change, 5 years−98.7%−79.8%
Beta (5Y)2.332.04
Employees16178
StockData Score
Total score17 (better)
Valuation score01 (better)
Growth score1 (better)0
Performance score01 (better)
Health score05 (better)
Dividend score00
Valuation
P/S101×15.4× (better)
P/B–0.9×
FCF yield−3.0% (better)−21.6%
Growth
Revenue growth (TTM)32.4% (better)−93.7%
Net income growth (TTM)–−543%
EPS growth (TTM)–−1287%
Profitability
Operating margin−312% (better)−698%
Net margin−235% (better)−572%
FCF margin−305% (better)−334%
Return on equity–−17.2%
Return on invested capital–−755%
Financial health
Debt / equity–0.00
Interest coverage−15.2×–
Current ratio0.5321.96 (better)
Altman Z-score−15.262.67 (better)
Piotroski F-score16 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions0.98%101%
Held by insiders2.8%53.3%
Insider net buying, 12 months–−$453K
Superinvestors holding1–
Short interest, % of float0.28%11.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.